For HER2-positive advanced gastric or gastroesophageal junction cancer, recent advances in the clinical development of molecular targeted therapy have enabled the use of trastuzumab as a standard therapy (27); however, similar regimens for the treatment of ESCC remain elusive. Here, ERBB2 is linked to esophageal squamous cell carcinoma.